Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC reduced its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 20.1% during the second quarter, Holdings Channel.com reports. The firm owned 7,053 shares of the specialty pharmaceutical company’s stock after selling 1,773 shares during the period. ProShare Advisors LLC’s holdings in Collegium Pharmaceutical were worth $227,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of COLL. Gladius Capital Management LP acquired a new position in Collegium Pharmaceutical during the 2nd quarter valued at about $32,000. nVerses Capital LLC increased its stake in shares of Collegium Pharmaceutical by 1,600.0% during the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,600 shares during the period. Sheaff Brock Investment Advisors LLC acquired a new stake in Collegium Pharmaceutical in the first quarter worth approximately $204,000. Gallacher Capital Management LLC bought a new position in Collegium Pharmaceutical during the 1st quarter valued at $223,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Collegium Pharmaceutical by 62.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,120 shares of the specialty pharmaceutical company’s stock valued at $238,000 after purchasing an additional 2,344 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on COLL shares. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and increased their target price for the company from $41.00 to $44.00 in a research note on Friday, June 7th. HC Wainwright lifted their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. Finally, Piper Sandler reiterated a “neutral” rating and set a $37.00 price objective (down previously from $39.00) on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.60.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas B. Smith sold 9,593 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the transaction, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by insiders.

Collegium Pharmaceutical Price Performance

COLL stock opened at $41.86 on Friday. The firm has a 50-day moving average of $37.22 and a two-hundred day moving average of $35.55. The firm has a market capitalization of $1.37 billion, a PE ratio of 17.44 and a beta of 0.94. The company has a current ratio of 1.11, a quick ratio of 1.04 and a debt-to-equity ratio of 1.71. Collegium Pharmaceutical, Inc. has a one year low of $20.95 and a one year high of $42.23.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The firm had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. During the same period in the previous year, the company posted $1.13 EPS. The company’s quarterly revenue was up 7.2% compared to the same quarter last year. On average, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.